Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
23.10
+0.35 (1.54%)
Mar 10, 2026, 1:56 PM CST
-12.33%
Market Cap 2.18B
Revenue (ttm) 184.91M
Net Income (ttm) -70.14M
Shares Out 95.95M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,272
Average Volume 111,659
Open 22.50
Previous Close 22.75
Day's Range 22.35 - 23.25
52-Week Range 19.80 - 33.65
Beta 0.05
RSI 31.13
Earnings Date Mar 27, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 34
Stock Exchange Taipei Exchange
Ticker Symbol 6704
Full Company Profile

Financial Performance

In 2024, TPEX:6704's revenue was 170.03 million, an increase of 20.44% compared to the previous year's 141.18 million. Losses were -83.32 million, -5.41% less than in 2023.

Financial Statements

News

There is no news available yet.